Crystal L. Hammond

Array ( [id] => 17251171 [patent_doc_number] => 11186643 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-30 [patent_title] => Anti-Axl antibodies [patent_app_type] => utility [patent_app_number] => 15/958076 [patent_app_country] => US [patent_app_date] => 2018-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 28650 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15958076 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16525263 [patent_doc_number] => 20200399343 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-24 [patent_title] => IMPROVED T CELL COMPOSITIONS AND METHODS [patent_app_type] => utility [patent_app_number] => 16/604690 [patent_app_country] => US [patent_app_date] => 2018-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16694 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16604690 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13508365 [patent_doc_number] => 20180305725 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-25 [patent_title] => Sialylated Glycoproteins [patent_app_type] => utility [patent_app_number] => 15/954146 [patent_app_country] => US [patent_app_date] => 2018-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17235 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15954146 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17890767 [patent_doc_number] => 11453720 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-27 [patent_title] => Anti-TIGIT antigen-binding proteins and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/498520 [patent_app_country] => US [patent_app_date] => 2018-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 48195 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 454 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498520 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15496365 [patent_doc_number] => 20200048371 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-13 [patent_title] => TUMOR ANTIGEN PRESENTATION INDUCER CONSTRUCTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/499808 [patent_app_country] => US [patent_app_date] => 2018-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36662 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16499808 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15175503 [patent_doc_number] => 20190358343 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => ADOPTIVE TRANSFER OF CAR T CELLS WITH SURFACE-CONJUGATED DRUG-LOADED NANOPARTICLES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/485033 [patent_app_country] => US [patent_app_date] => 2018-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20300 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16485033 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13778069 [patent_doc_number] => 20190002573 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-03 [patent_title] => CD123 SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 15/925182 [patent_app_country] => US [patent_app_date] => 2018-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32510 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15925182 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15618931 [patent_doc_number] => 20200079870 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-12 [patent_title] => CHIMERIC ANTIGEN RECEPTORS TARGETING CD37 [patent_app_type] => utility [patent_app_number] => 16/493142 [patent_app_country] => US [patent_app_date] => 2018-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19924 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16493142 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15345337 [patent_doc_number] => 20200010560 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-09 [patent_title] => METHOD [patent_app_type] => utility [patent_app_number] => 16/490972 [patent_app_country] => US [patent_app_date] => 2018-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28850 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16490972 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14836285 [patent_doc_number] => 20190276543 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-12 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING LATE STAGE LUNG CANCER [patent_app_type] => utility [patent_app_number] => 15/915359 [patent_app_country] => US [patent_app_date] => 2018-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14085 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15915359 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17363587 [patent_doc_number] => 11230604 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-01-25 [patent_title] => Antibodies against human CD38 [patent_app_type] => utility [patent_app_number] => 15/909540 [patent_app_country] => US [patent_app_date] => 2018-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 17 [patent_no_of_words] => 42117 [patent_no_of_claims] => 119 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15909540 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16072411 [patent_doc_number] => 20200190192 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-18 [patent_title] => PD-1/TIM-3 BI-SPECIFIC ANTIBODIES, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME [patent_app_type] => utility [patent_app_number] => 16/487806 [patent_app_country] => US [patent_app_date] => 2018-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 113144 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16487806 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16312351 [patent_doc_number] => 20200291089 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-17 [patent_title] => MULTIFUNCTIONAL MOLECULES COMPRISING A TRIMERIC LIGAND AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/486734 [patent_app_country] => US [patent_app_date] => 2018-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60229 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16486734 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12885103 [patent_doc_number] => 20180186876 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-05 [patent_title] => ANTI CD37 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 15/897400 [patent_app_country] => US [patent_app_date] => 2018-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18736 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15897400 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13504787 [patent_doc_number] => 20180303936 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-25 [patent_title] => COMBINATION THERAPY COMPRISING OX40 BINDING AGONISTS AND PD-1 AXIS BINDING ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 15/886454 [patent_app_country] => US [patent_app_date] => 2018-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55969 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -81 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15886454 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12813301 [patent_doc_number] => 20180162937 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-14 [patent_title] => ANTI-5T4 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/883759 [patent_app_country] => US [patent_app_date] => 2018-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27534 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15883759 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16444919 [patent_doc_number] => 10836831 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-17 [patent_title] => Anti-PTK7 antibodies and methods of use [patent_app_type] => utility [patent_app_number] => 15/882391 [patent_app_country] => US [patent_app_date] => 2018-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 42 [patent_no_of_words] => 52717 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15882391 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15178269 [patent_doc_number] => 20190359726 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => BCMA-TARGETING ANTIBODY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/479365 [patent_app_country] => US [patent_app_date] => 2018-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15648 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 179 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16479365 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19675951 [patent_doc_number] => 12187801 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-07 [patent_title] => Chimeric antigen receptors against AXL or ROR2 and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/478360 [patent_app_country] => US [patent_app_date] => 2018-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 41 [patent_no_of_words] => 64602 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 182 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16478360 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12750556 [patent_doc_number] => 20180142019 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-24 [patent_title] => THERAPEUTIC CD47 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 15/871802 [patent_app_country] => US [patent_app_date] => 2018-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44226 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15871802 [rel_patent_id] =>[rel_patent_doc_number] =>)